Publication

The Effect of SMN Gene Dosage on ALS Risk and Disease Severity.

Journal Paper/Review - Jan 15, 2021

Units
PubMed
Doi
Contact

Citation
Moisse M, Zwamborn R, Van Vugt J, van der Spek R, van Rheenen W, Kenna B, van Eijk K, Kenna K, Corcia P, Couratier P, Vourc'h P, Hardiman O, McLaughin R, Gotkine M, Drory V, Ticozzi N, Silani V, de Carvalho M, Mora J, Povedano M, Andersen P, Weber M, Başak N, Chen X, Eberle M, Al-Chalabi A, Shaw C, Openshaw P, Morrison K, Landers J, Glass J, Robberecht W, van Es M, Van den Berg L, Veldink J, Van Damme P, Project MinE Sequencing Consortium. The Effect of SMN Gene Dosage on ALS Risk and Disease Severity. Ann Neurol 2021; 89:686-697.
Type
Journal Paper/Review (English)
Journal
Ann Neurol 2021; 89
Publication Date
Jan 15, 2021
Issn Electronic
1531-8249
Pages
686-697
Brief description/objective

The role of the survival of motor neuron (SMN) gene in amyotrophic lateral sclerosis (ALS) is unclear, with several conflicting reports. A decisive result on this topic is needed, given that treatment options are available now for SMN deficiency.